quipazine quipazine quipazine is a serotonergic drug of the piperazine group which is used in scientific research. it was originally intended as an antidepressant but never developed for medical use. quipazineclinical dataatc codenoneidentifiers iupac name 2-piperazin-1-ylquinoline cas number4774-24-7 ypubchem cid5011iuphar/bps173chemspider4836 nunii4wcy05c0sjchemblchembl18772 ncomptox dashboard (epa)dtxsid3046952 echa infocard100.164.885 chemical and physical dataformulac13h15n3molar mass213.284 g·mol−13d model (jsmol)interactive image smiles c1cn(ccn1)c2=nc3=cc=cc=c3c=c2 inchi inchi=1s/c13h15n3/c1-2-4-12-11(3-1)5-6-13(15-12)16-9-7-14-8-10-16/h1-6,14h,7-10h2 nkey:xrxdajykgwnhtq-uhfffaoysa-n n ny (what is this?) (verify) pharmacology pharmacodynamics quipazine is a serotonin reuptake inhibitor, and also a moderately selective serotonin receptor agonist, binding to a range of different serotonin receptors, but particularly to the 5-ht2a and 5-ht3 subtypes. quipazine produces a head-twitch response and other psychedelic-consistent effects in animal studies including in mice, rats, and monkeys. however, it failed to produce psychedelic effects in humans at a dose of 25 mg, which was the highest dose tested due to 5-ht3 mediated side effects of nausea and gastrointestinal discomfort. however alexander shulgin claimed that a fully effective psychedelic dose could be reached by blocking 5-ht3 receptors using a 5-ht3 antagonist. chemistry quipazine is synthesized by reacting 2-chloroquinoline with piperazine. quipazine synthesis: